Secreted phospholipase A2 (sPLA2) isoforms are low molecular weight, millimolar calcium-dependent enzymes that hydrolyze the fatty acid from the sn-2 position of membrane phospholipids. Group IIA sPLA2, also known as sPLA2IIA and non-pancreatic sPLA2, has roles in the regulation of eicosanoid synthesis and may modulate inflammatory signaling. LY311727 is an inhibitor of Group IIA sPLA2 (IC50 = 0.47 μM) that interacts with the active site of the enzyme in a non-covalent manner. It shows greater than 1,500-fold selectivity over pancreatic sPLA2 (Group IB sPLA2). LY311727 is commonly used to distinguish the actions of Group IIA sPLA2 from those of other sPLA2 isoforms in biological systems.
LY311727 is an inhibitor of Group IIA sPLA2 (IC50 = 0.47 μM) that interacts with the active site of the enzyme in a non-covalent manner. It shows greater than 1,500-fold selectivity over pancreatic sPLA2 (Group IB sPLA2). LY311727 is commonly used to distinguish the actions of Group IIA sPLA2 from those of other sPLA2 isoforms in biological systems.[Cayman Chemical]
LY 311727 is an inhibitor of secretory phospholipase A2 (sPLA2) and can be used to block Pseudomonas aeruginosa cytotoxicity. It can also attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.
LY311727 is an orally active; potent secretory Phospholipase A2 (sPLA2; Group IIa) inhibitor.
